Menlo Park, CA, February 24, 2022 - CelerisTx Appoints Pharmaceuticals Industry Leader Peter Ho, M.D., Ph.D., to the Board of Directors

CelerisTx, the pioneer in AI-driven proximity-inducing compound discovery, today announced the appointment of Peter T.C. Ho, M.D., Ph.D., to the Board of Directors. Dr. Ho joins the Board of CelerisTx following multiple positions as a pharma executive. "Peter is a great inspiration to the entire biotech industry. His contributions to oncology have been tremendous for patients worldwide, and his expertise will support moving our programs into and through the clinical phases successfully. As founding President of BeiGene, he has helped to build one of the most successful biotech companies and has a long track record of transforming numerous investigational agents into approved therapies." said Christopher Trummer, Co-Founder, Chief Executive Officer, and President of Celeris Therapeutics.

"Targeted Protein Degradation holds unprecedented potential in oncology especially for molecular targets previously considered undruggable. The approaches that Celeris Therapeutics are pursuing, from productivity-enhancing R&D measures such as machine learning and automation, and structure-activity modeling to enhance parameters for clinical success convinced me to join the Board. I see the company uniquely positioned as a pioneer at the intersection of AI and proximity induction." said Dr. Ho. "The early-stage oncology programs, active collaborations with pharma, as well as expansion of the platform make it an exciting time to join the Board and work with an enthusiastic team to become a leading AI-first biopharma company making a difference for patients with unmet medical needs."

Dr. Ho received his B.A. in biology from The Johns Hopkins University and his M.D. and Ph.D. (pharmacology) degrees from Yale University, then completed a pediatrics residency at The Children's Hospital of Boston followed by clinical fellowships in pediatric hematology/oncology at the Dana-Farber Cancer Institute and in clinical oncology and regulatory sciences jointly through the U.S. FDA and the NCI. He began his career in drug discovery and development at the Investigational Drug Branch of the Cancer Therapy Evaluation Program, NCI followed by positions of increasing responsibility at Novartis and DuPont Pharmaceuticals. He subsequently served as Senior VP of the Oncology Center of Excellence in Drug Discovery at GlaxoSmithKline and VP of Oncology Clinical Development at Johnson and Johnson. In 2010, he cofounded BeiGene Ltd. and served as President. Most recently, he served as Chief Medical Officer at Epizyme Inc. and then at Boston Pharmaceuticals both of which are based in Cambridge, MA. Over his career, he has been directly responsible for the firsttime-in-human dosing of 19 anticancer agents and has overseen the development of over 60 hematology and oncology compounds in all phases of clinical trials. His work has contributed to eleven NCE or biologics approvals to date: Gleevec®; Arranon®; Tykerb®; Promacta®; Votrient®; Synribo®; Tafinlar®; Mekinist®; Sylvant®; and Rydap®, and Tazverik®.

About CelerisTx

Founded in 2020, CelerisTx is a US-Austrian, partially integrated drug discovery company focused on AI-driven development of novel proximity-inducing compounds to enable targeted protein degradation of pathogenic proteins. CelerisTx develops the Celeris One™ platform, a closed-loop development engine that predicts biomolecular interactions, generates new chemical matter that meets relevant degrader success criteria, and extends this knowledge to synthesis and biochemical validation. The application of this development engine promises to streamline the way potent degraders are discovered while increasing productivity in upstream research and development.

CelerisTx partners with pharma and biotech companies and develops its drug pipeline in the areas of neurodegenerative diseases and oncology. The offices are located in Menlo Park, California, and Graz, Austria, with laboratory operations to commence in the coming months.

More information on:

Back to news